Business
Exclusive Licence for Leading Gene Editing Tech
Exclusive Licence for Leading Gene Editing Tech.
About this update from Genus Plc
[{"type":"text","content":"\n \nRNS Number : 5258Y Genus PLC 18 May 2016 \n\n \nFOR IMMEDIATE RELEASE 18 May 2016\n \n Genus and Caribou Biosciences Announce Exclusive Collaboration\nfor Leading CRISPR-Cas9 Gene Editing Technology in Livestock Species\n \nGenus plc (LSE: GNS) (\"Genus\"), a global pioneer in animal genetics, and Caribou Biosciences, Inc. (\"Caribou\"), a leader in the revolutionary field of CRISPR-Cas gene editing, are pleased to announce a multi-year strategic collaboration where Genus receives a worldwide, exclusive license to Caribou's leading CRISPR-Cas9 gene editing technology platform in certain livestock species. This is a significant move for Genus and marks the largest technology-driven alliance that Genus has made to date. The partnership positions Caribou at the forefront of an emerging market for which CRISPR-Cas9 could have profound benefits to animal welfare and society. \nCaribou's market-leading CRISPR-Cas9 technology accurately targets and cuts DNA to produce precise and controllable changes to the genome. This partnership further strengthens Genus' leadership in applying gene editing technology to improve animal health and well-being. It will provide Caribou with opportunities within the animal genetics space and offers a novel gateway to apply its technology to help improve the welfare of food-producing animals. \nThe agreement gives Genus exclusive access to Caribou's CRISPR-Cas9 technology for the development of new traits in pigs, cattle and potentially other livestock species. In addition to an upfront payment, Caribou is eligible to receive regulatory and commercial milestone payments as well as royalties on licensed product sales from Genus. Additional terms of the agreement were not disclosed.\nCaribou and Genus will collaborate during...